ADRB2 and Alzheimer disease: We showed that extending treatment time from 1 to 2 months conferred significantly more beneficial impact on AD pathology in males but not females, highlighting the importance of defining duration and timing of β2AR stimulation in different sexes for optimal disease-modifying effects.